Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- cangrelor
- Kadcyla (ado-trastuzumab emtansine)
Interactions between your drugs
ado-trastuzumab emtansine cangrelor
Applies to: Kadcyla (ado-trastuzumab emtansine), cangrelor
MONITOR CLOSELY: Coadministration of trastuzumab emtansine with anticoagulant or antiplatelet drugs may potentiate the risk of hemorrhagic events associated with these drugs. In clinical trials, fatal cases of hemorrhage occurred in patients receiving trastuzumab emtansine in addition to anticoagulant and antiplatelet therapy.
MANAGEMENT: Caution is recommended and additional monitoring should be considered if trastuzumab emtansine must be used with anticoagulant or antiplatelet drugs. In general, monitoring of platelet counts is recommended prior to each dose of trastuzumab emtansine. If platelet counts decrease to less than 50,000/mm3 (Grade 3 or higher), discontinue trastuzumab emtansine until platelet counts increase to 75,000/mm3 or higher (Grade 1 or less).
References (3)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2022) "Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Plavix
Plavix (clopidogrel) is used to prevent blood clots after a recent heart attack or stroke. Includes ...
Integrilin
Integrilin prevents blood clots or heart attack in people with severe chest pain and in patients ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Angiomax
Angiomax is used for angina, percutaneous coronary intervention
ReoPro
ReoPro is used to lessen the chance of heart attack in people who need percutaneous coronary ...
Abciximab
Abciximab is used for high risk percutaneous transluminal angioplasty
Eptifibatide
Eptifibatide is used for acute coronary syndrome, angina, heart attack, percutaneous coronary ...
Bivalirudin
Bivalirudin is used for angina, percutaneous coronary intervention
Clopidogrel
Clopidogrel is used for acute coronary syndrome, acute coronary syndrome, prophylaxis, heart ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.